menu
    • menu
    [{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lisinopril","moa":"ACE","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yiling Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yiling Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Alvogen","sponsor":"AZTIQ PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Lisinopril","moa":"ACE","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alvogen","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Alvogen \/ Aztiq","highestDevelopmentStatusID":"12","companyTruncated":"Alvogen \/ Aztiq"},{"orgOrder":0,"company":"ALMATICA PHARMA INC","sponsor":"TWi Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Lisinopril","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ALMATICA PHARMA INC","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals, Inc."}]

    Find Clinical Drug Pipeline Developments & Deals for Lisinopril

    Menu

    Lisinopril

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ALMATICA PHARMA INC

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ALMATICA PHARMA INC

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : TWi Pharmaceuticals

                            Deal Size : $38.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bora Acquires Six US Brand Product Licenses, Rights

                            Details : Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.

                            Brand Name : Zestril

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 18, 2023

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : TWi Pharmaceuticals

                            Deal Size : $38.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alvogen

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alvogen

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : AZTIQ PHARMA

                            Deal Size : $350.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aztiq Buys 17% Stake in Alvogen US

                            Details : Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.

                            Brand Name : Zestril

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 30, 2021

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : AZTIQ PHARMA

                            Deal Size : $350.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Yiling Pharmaceutical

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Yiling Pharmaceutical

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market

                            Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 19, 2020

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth